‘Small mol­e­cules are sexy again’: Gate Bio­science de­buts with $60M and a new way to stop dis­ease-caus­ing pro­teins

Gate Bio­science has raised $60 mil­lion to de­vel­op a new type of pill-based med­i­cine — which it calls a mol­e­c­u­lar gate — that can go af­ter the spec­trum of ma­li­cious pro­teins.

The Bris­bane, CA biotech was start­ed in 2021 by Jor­di Ma­ta‐Fink, a mem­ber of the found­ing team for Gen­er­ate:Bio­med­i­cines and now Gate’s CEO; Pat Sharp, whose post­doc work serves as the foun­da­tion for the com­pa­ny’s plat­form; and Ra­man Tal­war, a for­mer se­nior as­so­ciate at Flag­ship Pi­o­neer­ing. The Se­ries A round was led by Ver­sant Ven­tures and An­dreessen Horowitz (a16z), and in­vestors al­so in­clud­ed ARCH Ven­ture Part­ners and GV, Google’s ven­ture arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER